Literature DB >> 27402879

Parent-of-origin tumourigenesis is mediated by an essential imprinted modifier in SDHD-linked paragangliomas: SLC22A18 and CDKN1C are candidate tumour modifiers.

Attje S Hoekstra1, Ruben D Addie2,3, Cor Ras4, Reza M Seifar4, Claudia A Ruivenkamp5, Inge H Briaire-de Bruijn3, Frederik J Hes5, Jeroen C Jansen6, Eleonora P M Corssmit7, Willem E Corver3, Hans Morreau3, Judith V M G Bovée3, Jean-Pierre Bayley1, Peter Devilee8,3.   

Abstract

Mutations in SDHD and SDHAF2 (both located on chromosome 11) give rise to hereditary paraganglioma almost exclusively after paternal transmission of the mutation, and tumours often show loss of the entire maternal copy of chromosome 11. The 'Hensen' model postulates that a tumour modifier gene located on chromosome 11p15, a region known to harbour a cluster of imprinted genes, is essential to tumour formation. We observed decreased protein expression of the 11p15 candidate genes CDKN1C, SLC22A18 and ZNF215 evaluated in 60 SDHD-mutated tumours compared to normal carotid body tissue and non-SDH mutant tumours.We then created stable knockdown in vitro models, reasoning that the simultaneous knockdown of SDHD and a maternally expressed 11p15 modifier gene would enhance paraganglioma-related cellular characteristics compared to SDHD knockdown alone. Knockdown of SDHD in SNB19 and SHSY5Y cells resulted in the accumulation of succinate, the stabilization of HIF1 protein and a reduction in cell proliferation.Compared to single knockdown of SDHD, knockdown of SDHD together with SLC22A18 or with CDKN1C led to small but significant increases in cell proliferation and resistance to apoptosis, and to a gene expression profile closely related to the known transcriptional profile of SDH-deficient tumours. Of the 60 SDHD tumours investigated, four tumours showing retention of chromosome 11 showed SLC22A18 and CDKN1C expression levels comparable to levels in tumours showing loss of chromosome 11, suggesting loss of protein expression despite chromosomal retention.Our data strongly suggest that SLC22A18 and/or CDKN1C are tumour modifier genes involved in the tumourigenesis of SDHD-linked paraganglioma.
© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27402879     DOI: 10.1093/hmg/ddw218

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  8 in total

1.  SDHB-related pheochromocytoma and paraganglioma penetrance and genotype-phenotype correlations.

Authors:  Ivana Jochmanova; Katherine I Wolf; Kathryn S King; Joan Nambuba; Robert Wesley; Victoria Martucci; Margarita Raygada; Karen T Adams; Tamara Prodanov; Antonio Tito Fojo; Ivica Lazurova; Karel Pacak
Journal:  J Cancer Res Clin Oncol       Date:  2017-04-03       Impact factor: 4.553

2.  Observational study of population genomic screening for variants associated with endocrine tumor syndromes in a large, healthcare-based cohort.

Authors:  Juliann M Savatt; Nicole M Ortiz; Gretchen M Thone; Whitney S McDonald; Melissa A Kelly; Alexander S F Berry; Madiha M Alvi; Miranda L G Hallquist; Jennifer Malinowski; Nicholas C Purdy; Marc S Williams; Amy C Sturm; Adam H Buchanan
Journal:  BMC Med       Date:  2022-06-07       Impact factor: 11.150

3.  Clinical progression and metachronous paragangliomas in a large cohort of SDHD germline variant carriers.

Authors:  Berdine L Heesterman; Lisa M H de Pont; Andel Gl van der Mey; Jean-Pierre Bayley; Eleonora Pm Corssmit; Frederik J Hes; Berit M Verbist; Peter Paul G van Benthem; Jeroen C Jansen
Journal:  Eur J Hum Genet       Date:  2018-05-18       Impact factor: 4.246

Review 4.  Metabologenomics of Phaeochromocytoma and Paraganglioma: An Integrated Approach for Personalised Biochemical and Genetic Testing.

Authors:  Graeme Eisenhofer; Barbara Klink; Susan Richter; Jacques Wm Lenders; Mercedes Robledo
Journal:  Clin Biochem Rev       Date:  2017-04

5.  Loss of maternal chromosome 11 is a signature event in SDHAF2, SDHD, and VHL-related paragangliomas, but less significant in SDHB-related paragangliomas.

Authors:  Attje S Hoekstra; Erik F Hensen; Ekaterina S Jordanova; Esther Korpershoek; Anouk Na van der Horst-Schrivers; Cees Cornelisse; Eleonora P M Corssmit; Frederik J Hes; Jeroen C Jansen; Henricus P M Kunst; Henri J L M Timmers; Adrian Bateman; Diana Eccles; Judith V M G Bovée; Peter Devilee; Jean-Pierre Bayley
Journal:  Oncotarget       Date:  2017-02-28

6.  Epigenome-wide skeletal muscle DNA methylation profiles at the background of distinct metabolic types and ryanodine receptor variation in pigs.

Authors:  Siriluck Ponsuksili; Nares Trakooljul; Sajjanar Basavaraj; Frieder Hadlich; Eduard Murani; Klaus Wimmers
Journal:  BMC Genomics       Date:  2019-06-13       Impact factor: 3.969

Review 7.  Succinate dehydrogenase and MYC-associated factor X mutations in pituitary neuroendocrine tumours.

Authors:  Paul Benjamin Loughrey; Federico Roncaroli; Estelle Healy; Philip Weir; Madhu Basetti; Ruth T Casey; Steven J Hunter; Márta Korbonits
Journal:  Endocr Relat Cancer       Date:  2022-09-02       Impact factor: 5.900

8.  Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes SDHB, SDHC and SDHD.

Authors:  Katrina A Andrews; David B Ascher; Douglas Eduardo Valente Pires; Daniel R Barnes; Lindsey Vialard; Ruth T Casey; Nicola Bradshaw; Julian Adlard; Simon Aylwin; Paul Brennan; Carole Brewer; Trevor Cole; Jackie A Cook; Rosemarie Davidson; Alan Donaldson; Alan Fryer; Lynn Greenhalgh; Shirley V Hodgson; Richard Irving; Fiona Lalloo; Michelle McConachie; Vivienne P M McConnell; Patrick J Morrison; Victoria Murday; Soo-Mi Park; Helen L Simpson; Katie Snape; Susan Stewart; Susan E Tomkins; Yvonne Wallis; Louise Izatt; David Goudie; Robert S Lindsay; Colin G Perry; Emma R Woodward; Antonis C Antoniou; Eamonn R Maher
Journal:  J Med Genet       Date:  2018-01-31       Impact factor: 6.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.